|
1
|
Hodi FS, O’Day SJ, McDermott DF, et al:
Improved survival with ipilimumab in patients with metastatic
melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar
|
|
2
|
Robert C, Thomas L, Bondarenko I, et al:
Ipilimumab plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chapman PB, Hauschild A, Robert C, et al:
Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Flaherty KT, Puzanov I, Kim KB, et al:
Inhibition of mutated, activated BRAF in metastatic melanoma. N
Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bedikian AY, Millward M, Pehamberger H, et
al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in
patients with advanced melanoma: the Oblimersen Melanoma Study
Group. J Clin Oncol. 24:4738–4745. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chapman PB, Einhorn LH, Meyers ML, et al:
Phase III multicenter randomized trial of the Dartmouth regimen
versus dacarbazine in patients with metastatic melanoma. J Clin
Oncol. 17:2745–2751. 1999.PubMed/NCBI
|
|
7
|
Stevens MF, Hickman JA, Langdon SP, et al:
Antitumor activity and pharmacokinetics in mice of
8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one
(CCRG 81045; M&B 39831), a novel drug with potential as an
alternative to dacarbazine. Cancer Res. 47:5846–5852.
1987.PubMed/NCBI
|
|
8
|
Tsang LL, Quarterman CP, Gescher A and
Slack JA: Comparison of the cytotoxicity in vitro of temozolomide
and dacarbazine, prodrugs of
3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother
Pharmacol. 27:342–346. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ingold B, Schraml P, Heppner FL and Moch
H: Homogeneous MGMT immunoreactivity correlates with an
unmethylated MGMT promoter status in brain metastases of various
solid tumors. PLoS One. 4:e47752009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Newlands ES, Blackledge GR, Slack JA, et
al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC
362856). Br J Cancer. 65:287–291. 1992. View Article : Google Scholar
|
|
12
|
Bleehen NM, Newlands ES, Lee SM, et al:
Cancer Research Campaign phase II trial of temozolomide in
metastatic melanoma. J Clin Oncol. 13:910–913. 1995.PubMed/NCBI
|
|
13
|
Middleton MR, Grob JJ, Aaronson N, et al:
Randomized phase III study of temozolomide versus dacarbazine in
the treatment of patients with advanced metastatic malignant
melanoma. J Clin Oncol. 18:158–166. 2000.PubMed/NCBI
|
|
14
|
Patel PM, Suciu S, Mortier L, et al:
Extended schedule, escalated dose temozolomide versus dacarbazine
in stage IV melanoma: Final results of a randomised phase III study
(EORTC 18032). Eur J Cancer. 47:1476–1483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kabbinavar F, Hurwitz HI, Fehrenbacher L,
et al: Phase II, randomized trial comparing bevacizumab plus
fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with
metastatic colorectal cancer. J Clin Oncol. 21:60–65. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Johnson DH, Fehrenbacher L, Novotny WF, et
al: Randomized phase II trial comparing bevacizumab plus
carboplatin and paclitaxel with carboplatin and paclitaxel alone in
previously untreated locally advanced or metastatic non-small-cell
lung cancer. J Clin Oncol. 22:2184–2191. 2004. View Article : Google Scholar
|
|
17
|
von Moos R, Seifert B, Simcock M, et al:
First-line temozolomide combined with bevacizumab in metastatic
melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol.
23:531–536. 2011.PubMed/NCBI
|
|
18
|
Rietschel P, Wolchok JD, Krown S, et al:
Phase II study of extended-dose temozolomide in patients with
melanoma. J Clin Oncol. 26:2299–2304. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Palmisano WA, Divine KK, Saccomanno G, et
al: Predicting lung cancer by detecting aberrant promoter
methylation in sputum. Cancer Res. 60:5954–5958. 2000.PubMed/NCBI
|
|
20
|
Kohonen-Corish MR, Cooper WA, Saab J,
Thompson JF, Tren RJ and Millward MJ: Promoter hypermethylation of
the O(6)-methylguanine DNA methyltransferase gene and
microsatellite instability in metastatic melanoma. J Invest
Dermatol. 126:167–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rastetter M, Schagdarsurengin U, Lahtz C,
et al: Frequent intra-tumoural heterogeneity of promoter
hypermethylation in malignant melanoma. Histol Histopathol.
22:1005–1015. 2007.PubMed/NCBI
|
|
22
|
Fritz G, Tano K, Mitra S and Kaina B:
Inducibility of the DNA repair gene encoding
O6-methylguanine-DNA methyltransferase in mammalian
cells by DNA-damaging treatments. Mol Cell Biol. 11:4660–4668.
1991.PubMed/NCBI
|
|
23
|
Grombacher T, Mitra S and Kaina B:
Induction of the alkyltransferase (MGMT) gene by DNA damaging
agents and the glucocorticoid dexamethasone and comparison with the
response of base excision repair genes. Carcinogenesis.
17:2329–2336. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hassel JC, Sucker A, Edler L, et al: MGMT
gene promoter methylation correlates with tolerance of temozolomide
treatment in melanoma but not with clinical outcome. Br J Cancer.
103:820–826. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hamilton MG, Roldan G, Magliocco A,
McIntyre JB, Parney I and Easaw JC: Determination of the
methylation status of MGMT in different regions within glioblastoma
multiforme. J Neurooncol. 102:255–260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Preusser M, Elezi L and Hainfellner JA:
Reliability and reproducibility of PCR-based testing of
O6-methylguanine-DNA methyltransferase gene (MGMT)
promoter methylation status in formalin-fixed and paraffin-embedded
neurosurgical biopsy specimens. Clin Neuropathol. 27:388–390.
2008.PubMed/NCBI
|
